Protein oxidative modifications in the ageing brain: Consequence for the onset of neurodegenerative disease

References

• Breimer LH. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol Carcinog 1990;3:188–197.
   PubMed Web of Science ®Google Scholar
• Meneghini R. Iron homeostasis, oxidative stress, and DNA damage. Free Radic Biol Med 1997;23:783–792.
   PubMed Web of Science ®Google Scholar
• McLennan HR, Degli EM. The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. J Bioenerg Biomembr 2000;32:153–162.
   PubMed Web of Science ®Google Scholar
• Thelen M, Dewald B, Baggiolini M. Neutrophil signal transduction and activation of the respiratory burst. Physiol Rev 1993;73:797–821.
   PubMed Web of Science ®Google Scholar
• Ward JF. The complexity of DNA damage: relevance to biological consequences. Int J Radiat Biol 1994;66:427–432.
   PubMed Web of Science ®Google Scholar
• Breen AP, Murphy JA. Reactions of oxyl radicals with DNA. Free Radic Biol Med 1995;18:1033–1077.
   PubMed Web of Science ®Google Scholar
• Rosen GM, Pou S, Ramos CL, Cohen MS, Britigan BE. Free radicals and phagocytic cells. FASEB J 1995;9:200–209.
   PubMed Web of Science ®Google Scholar
• Mendoza-Nunez VM, Ruiz-Ramos M, Sanchez-Rodriguez MA, Retana-Ugalde R, Munoz-Sanchez JL. Aging-related oxidative stress in healthy humans. Tohoku J Exp Med 2007;213:261–268.
   PubMed Web of Science ®Google Scholar
• Stadtman ER. Role of oxidant species in aging. Curr Med Chem 2004;11:1105–1112.
   PubMed Web of Science ®Google Scholar
• Stadtman ER. Protein oxidation and aging. Science 1992;257:1220–1224.
   PubMed Web of Science ®Google Scholar
• Stadtman ER, Van RH, Richardson A, Wehr NB, Levine RL. Methionine oxidation and aging. Biochim Biophys Acta 2005;1703:135–140.
   PubMed Web of Science ®Google Scholar
• van der Vliet A, Eiserich JP, O'Neill CA, Halliwell B, Cross CE. Tyrosine modification by reactive nitrogen species: a closer look. Arch Biochem Biophys 1995;319:341–349.
   PubMed Web of Science ®Google Scholar
• Baynes JW. The role of AGEs in aging: causation or correlation. Exp Gerontol 2001;36:1527–1537.
   PubMed Web of Science ®Google Scholar
• Robinson NE, Robinson AB. Deamidation of human proteins. Proc Natl Acad Sci USA 2001;98:12409–12413.
   PubMed Web of Science ®Google Scholar
• McCudden CR, Kraus VB. Biochemistry of amino acid racemization and clinical application to musculoskeletal disease. Clin Biochem 2006;39:1112–1130.
   Google Scholar
• Uversky VN, Eliezer D. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci 2009;10:483–499.
   PubMed Web of Science ®Google Scholar
• Levine RL. Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med 2002;32:790–796.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kajkenova O, Feuers RJ, Udupa KB, Desai VG, Epstein J, Hart RW, Lipschitz DA. Impaired glutathione peroxidase activity accounts for the age-related accumulation of hydrogen peroxide in activated human neutrophils. J Gerontol A Biol Sci Med Sci 1998;53:M169–M175.
   Google Scholar
• Bancher C, Grundke-Iqbal I, Iqbal K, Fried VA, Smith HT, Wisniewski HM. Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease. Brain Res 1991;539:11–18.
   PubMed Web of Science ®Google Scholar
• Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83;4913–4917.
   PubMed Web of Science ®Google Scholar
• Smith MA, Drew KL, Nunomura A, Takeda A, Hirai K, Zhu X, Atwood CS, Raina AK, Rottkamp CA, Sayre LM, Friedland RP, Perry G. Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochem Int 2002;40:527–531.
   PubMedGoogle Scholar
• Williams A. Defining neurodegenerative diseases. BMJ 2002;324:1465–1466.
   Google Scholar
• Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 2003;111:163–169.
   PubMed Web of Science ®Google Scholar
• Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416: 507–511.
   PubMed Web of Science ®Google Scholar
• Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001;292:1552–1555.
   PubMed Web of Science ®Google Scholar
• Hayflick L. Biological aging is no longer an unsolved problem. Ann N Y Acad Sci 2007;1100:1–13.
   PubMed Web of Science ®Google Scholar
• Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005;120:483–495.
   PubMed Web of Science ®Google Scholar
• Kirkwood TB. Understanding the odd science of aging. Cell 2005;120:437–447.
   PubMed Web of Science ®Google Scholar
• Friedman DB, Johnson TE. A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genetics 1988;118:75–86.
   PubMed Web of Science ®Google Scholar
• Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature 1993;366:461–464.
   PubMed Web of Science ®Google Scholar
• Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, Morrow JD, Van RH, Sedivy JM, Yamasoba T, Tanokura M, Weindruch R, Leeuwenburgh C, Prolla TA. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005;309:481–484.
   PubMed Web of Science ®Google Scholar
• Wiesner RJ, Zsurka G, Kunz WS. Mitochondrial DNA damage and the aging process: facts and imaginations. Free Radic Res 2006;40:1284–1294.
   PubMed Web of Science ®Google Scholar
• Friguet B. Oxidized protein degradation and repair in ageing and oxidative stress. FEBS Lett 2006;580:2910–2916.
   PubMed Web of Science ®Google Scholar
• Friguet B, Bulteau AL, Chondrogianni N, Conconi M, Petropoulos I. Protein degradation by the proteasome and its implications in aging. Ann N Y Acad Sci 2000;908:143–154.
   PubMedGoogle Scholar
• Schoneich C. Protein modification in aging: an update. Exp Gerontol 2006;41:807–812.
   PubMed Web of Science ®Google Scholar
• Stadtman ER, Levine RL. Protein oxidation. Ann N Y Acad Sci 2000;899:191–208.
   PubMed Web of Science ®Google Scholar
• Farout L, Friguet B. Proteasome function in aging and oxidative stress: implications in protein maintenance failure. Antioxid Redox Signal 2006;8:205–216.
   PubMed Web of Science ®Google Scholar
• Keller JN, Huang FF, Markesbery WR. Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 2000;98:149–156.
   PubMedGoogle Scholar
• Petropoulos I, Conconi M, Wang X, Hoenel B, Bregegere F, Milner Y, Friguet B. Increase of oxidatively modified protein is associated with a decrease of proteasome activity and content in aging epidermal cells. J Gerontol A Biol Sci Med Sci 2000;55:B220–B227.
   PubMedGoogle Scholar
• Grune T, Jung T, Merker K, Davies KJ. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and ‘aggresomes’ during oxidative stress, aging, and disease. Int J Biochem Cell Biol 2004;36:2519–2530.
   PubMed Web of Science ®Google Scholar
• Sitte N, Merker K, Von ZT, Grune T, Davies KJ. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I–effects of proliferative senescence. FASEB J 2000;14:2495–2502.
   PubMed Web of Science ®Google Scholar
• Sitte N, Merker K, Von ZT, Davies KJ, Grune T. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part II–aging of nondividing cells. FASEB J 2000;14:2503–2510.
   PubMed Web of Science ®Google Scholar
• Sitte N, Merker K, Von ZT, Grune T. Protein oxidation and degradation during proliferative senescence of human MRC-5 fibroblasts. Free Radic Biol Med 2000;28: 701–708.
   PubMed Web of Science ®Google Scholar
• Grune T, Merker K, Jung T, Sitte N, Davies KJ. Protein oxidation and degradation during postmitotic senescence. Free Radic Biol Med 2005;39:1208–1215.
   Google Scholar
• Chondrogianni N, Stratford FL, Trougakos IP, Friguet B, Rivett AJ, Gonos ES. Central role of the proteasome in senescence and survival of human fibroblasts: induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation. J Biol Chem 2003;278: 28026–28037.
   PubMed Web of Science ®Google Scholar
• Picot CR, Perichon M, Cintrat JC, Friguet B, Petropoulos I. The peptide methionine sulfoxide reductases, MsrA and MsrB (hCBS-1), are downregulated during replicative senescence of human WI-38 fibroblasts. FEBS Lett 2004;558: 74–78.
   PubMed Web of Science ®Google Scholar
• Verbeke P, Clark BF, Rattan SI. Reduced levels of oxidized and glycoxidized proteins in human fibroblasts exposed to repeated mild heat shock during serial passaging in vitro. Free Radic Biol Med 2005;31:1593–1602.
   Google Scholar
• Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998;78:547–581.
   PubMed Web of Science ®Google Scholar
• Uchida K. Lipofuscin-like fluorophores originated from malondialdehyde. Free Radic Res 2006;40:1335–1338.
   PubMed Web of Science ®Google Scholar
• Kurz T, Terman A, Brunk UT. Autophagy, ageing and apoptosis: the role of oxidative stress and lysosomal iron. Arch Biochem Biophys 2007;462:220–230.
   PubMed Web of Science ®Google Scholar
• Terman A. Catabolic insufficiency and aging. Ann N Y Acad Sci 2006;1067:27–36.
   Web of Science ®Google Scholar
• Krohne TU, Stratmann NK, Kopitz J, Holz FG. Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp Eye Res 2010;90:465–471.
   PubMed Web of Science ®Google Scholar
• Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon C. A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet 2008;4:e24.
   PubMed Web of Science ®Google Scholar
• Nakanishi H, Wu Z. Microglia-aging: roles of microglial lysosome- and mitochondria-derived reactive oxygen species in brain aging. Behav Brain Res 2009;201:1–7.
   PubMed Web of Science ®Google Scholar
• Tsay HJ, Wang P, Wang SL, Ku HH. Age-associated changes of superoxide dismutase and catalase activities in the rat brain. J Biomed Sci 2000;7:466–474.
   PubMed Web of Science ®Google Scholar
• Siqueira IR, Fochesatto C, de Andrade A, Santos M, Hagen M, Bello-Klein A, Netto CA. Total antioxidant capacity is impaired in different structures from aged rat brain. Int J Dev Neurosci 2005;23:663–671.
   PubMed Web of Science ®Google Scholar
• Davies KJ, Delsignore ME, Lin SW. Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J Biol Chem 1987;262:9902–9907.
   PubMed Web of Science ®Google Scholar
• Cakatay U, Telci A, Kayali R, Tekeli F, Akcay T, Sivas A. Relation of oxidative protein damage and nitrotyrosine levels in the aging rat brain. Exp Gerontol 2001;36:221–229.
   PubMedGoogle Scholar
• Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994;91:5710–5714.
   PubMed Web of Science ®Google Scholar
• Munch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev 1997;23:134–143.
   PubMed Web of Science ®Google Scholar
• Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P. Crosslinking of alpha-synuclein by advanced glycation endproducts–an early pathophysiological step in Lewy body formation? J Chem Neuroanat 2000;20:253–257.
   PubMed Web of Science ®Google Scholar
• Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 1998;153:1149–1155.
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443: 787–795.
   PubMed Web of Science ®Google Scholar
• Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006;8:2061–2073.
   PubMed Web of Science ®Google Scholar
• Nunomura A, Moreira PI, Lee HG, Zhu X, Castellani RJ, Smith MA, Perry G. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Targets 2007;6:411–423.
   PubMedGoogle Scholar
• Kokoszka JE, Coskun P, Esposito LA, Wallace DC. Increased mitochondrial oxidative stress in the Sod2 (+/−) mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proc Natl Acad Sci USA 2001;98:2278–2283.
   PubMed Web of Science ®Google Scholar
• Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119–130.
   PubMed Web of Science ®Google Scholar
• Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000;23298–304.
   PubMed Web of Science ®Google Scholar
• Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med 2009;30:191–296.
   PubMed Web of Science ®Google Scholar
• Ohshima H, Pignatelli B, Li CQ, Baflast S, Gilibert I, Boffetta P. Analysis of oxidized and nitrated proteins in plasma and tissues as biomarkers for exposure to reactive oxygen and nitrogen species. IARC Sci Publ 2002;156; 393–394.
   Google Scholar
• Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006;97:1634–1658.
   PubMed Web of Science ®Google Scholar
• Bose S, Mason GG, Rivett AJ. Phosphorylation of proteasomes in mammalian cells. Mol Biol Rep 1999;26:11–14.
   PubMedGoogle Scholar
• Ciechanover A, Schwartz AL. The ubiquitin-mediated proteolytic pathway: mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins. FASEB J 1994;8:182–191.
   PubMed Web of Science ®Google Scholar
• Reinheckel T, Sitte N, Ullrich O, Kuckelkorn U, Davies KJ, Grune T. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J 1998;335: 637–642.
   PubMed Web of Science ®Google Scholar
• Reinheckel T, Ullrich O, Sitte N, Grune T. Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch Biochem Biophys 2000;377:65–68.
   PubMed Web of Science ®Google Scholar
• Jariel-Encontre I, Bossis G, Piechaczyk M. Ubiquitin-independent degradation of proteins by the proteasome. Biochim Biophys Acta 2008;1786:153–177.
   PubMed Web of Science ®Google Scholar
• Medicherla B, Goldberg AL. Heat shock and oxygen radicals stimulate ubiquitin-dependent degradation mainly of newly synthesized proteins. J Cell Biol 2008;182:663–673.
   PubMed Web of Science ®Google Scholar
• Orr HT. Neurodegenerative disease: neuron protection agency. Nature 2004;431:747–748.
   Google Scholar
• Sitte, N, Huber M, Grune T, Ladhoff A, Doecke WD, Von ZT, Davies KJ. Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts. FASEB J 2000;14:1490–1498.
   PubMed Web of Science ®Google Scholar
• Hohn A, Jung T, Grimm S, Grune T. Lipofuscin-bound iron is a major intracellular source of oxidants: role in senescent cells. Free Radic Biol Med 2010;48:1100–1108.
   PubMed Web of Science ®Google Scholar
• Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004;24:565–575.
   PubMed Web of Science ®Google Scholar
• Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326–1329.
   PubMed Web of Science ®Google Scholar
• Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 2001;79:1246–1249.
   PubMed Web of Science ®Google Scholar
• Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134–147.
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001;98: 12245–12250.
   PubMedGoogle Scholar
• Brown DR. Brain proteins that mind metals: a neurodegenerative perspective. Dalton Trans 2009;7:4069–4076.
   Google Scholar
• Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004;363:1139–1146.
   PubMed Web of Science ®Google Scholar
• Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999;81: 163–221.
   PubMed Web of Science ®Google Scholar
• Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9:768–778.
   PubMed Web of Science ®Google Scholar
• Iqbal K, Liu F, Gong CX, Alonso AC, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009;118:53–69.
   PubMed Web of Science ®Google Scholar
• Alonso AC, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 2004;279: 34873–34881.
   Google Scholar
• Wang JZ, Gong CX, Zaidi T, Grundke-Iqbal I, Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem 1995;270: 4854–4860.
   Google Scholar
• Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999;340:1970–1980.
   PubMed Web of Science ®Google Scholar
• Baum L, Chen L, Ng HK, Pang CP. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology. Microsc Res Tech 2000;50:278–281.
   Google Scholar
• Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:1487–1491.
   PubMed Web of Science ®Google Scholar
• Gotz J, Chen F, van DJ, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293:1491–1495.
   PubMed Web of Science ®Google Scholar
• Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631–639.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487–498.
   PubMed Web of Science ®Google Scholar
• Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430:631–639.
   PubMed Web of Science ®Google Scholar
• Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D'Arrigo C, Bachi A, Cattaneo A, Canale C, Torrassa S, Saido TC, Markesbery W, Gambetti P, Tabaton M. beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 2005;280:34186–34192.
   PubMed Web of Science ®Google Scholar
• Mandrekar-Colucci S, Landreth GE. Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets 2010;9:156–167.
   PubMed Web of Science ®Google Scholar
• Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665–676.
   PubMed Web of Science ®Google Scholar
• Venisti Zarom L, Chen J, Regan RF. The oxidative neurotoxictiy of clioquinol. Neuropharmacology 2005;49:687–694.
   Google Scholar
• Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001;276:20466–20473.
   PubMed Web of Science ®Google Scholar
• Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters CL, Tanzi RE, Inestrosa NC, Bush AI. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 2002;277:40302–40308.
   PubMed Web of Science ®Google Scholar
• Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999;38:7609–7616.
   PubMed Web of Science ®Google Scholar
• Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000;74:270–279.
   PubMed Web of Science ®Google Scholar
• Yan SD, Stern DM. Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD). Int J Exp Pathol 2005;86:161–171.
   Google Scholar
• Szaingurten-Solodkin I, Hadad N, Levy R. Regulatory role of cytosolic phospholipase A2alpha in NADPH oxidase activity and in inducible nitric oxide synthase induction by aggregated Abeta1-42 in microglia. Glia 2009;57:1727–1740.
   PubMed Web of Science ®Google Scholar
• Pratico D, Zhukareva V, Yao Y, Uryu K, Funk CD, Lawson JA, Trojanowski JQ, Lee VM. 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol 2004;164:1655–1662.
   PubMed Web of Science ®Google Scholar
• Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001;21:3017–3023.
   PubMed Web of Science ®Google Scholar
• Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S–629S.
   PubMed Web of Science ®Google Scholar
• Montine KS, Reich E, Neely MD, Sidell KR, Olson SJ, Markesbery WR, Montine TJ. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 1998;57:415–425.
   PubMed Web of Science ®Google Scholar
• Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 2005;93:953–962.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 2005;92:255–263.
   PubMed Web of Science ®Google Scholar
• Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 2005;280:11648–11655.
   PubMed Web of Science ®Google Scholar
• Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357–366.
   PubMed Web of Science ®Google Scholar
• Mattson MP, Lovell MA, Furukawa K, Markesbery WR. Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 1995;65: 1740–1751.
   PubMed Web of Science ®Google Scholar
• Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994;91:3270–3274.
   PubMed Web of Science ®Google Scholar
• Mattson MP. Advances fuel Alzheimer's conundrum. Nat Genet 1997;17:254–256.
   PubMed Web of Science ®Google Scholar
• Mark RJ, Blanc EM, Mattson MP. Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease. Mol Neurobiol 1996;12:211–224.
   PubMed Web of Science ®Google Scholar
• Rosenberg RN. The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. Neurology 2000;54:2045–2054.
   PubMed Web of Science ®Google Scholar
• Wong A, Luth HJ, Uther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T, Munch G. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res 2001;920: 32–40.
   PubMed Web of Science ®Google Scholar
• Moskovitz J, Bar-Noy S, Williams WM, Requena J, Berlett BS, Stadtman ER. Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc Natl Acad Sci USA 2001;98:12920–12925.
   PubMed Web of Science ®Google Scholar
• Poppek D, Keck S, Ermak G, Jung T, Stolzing A, Ullrich O, Davies KJ, Grune T. Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem J 2006;400:511–520.
   PubMed Web of Science ®Google Scholar
• Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003;85:115–122.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC, Hisatomi T, Mochizuki M, Morita I. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 2005;115:2793–2800.
   PubMed Web of Science ®Google Scholar
• Fratta P, Engel WK, McFerrin J, Davies KJ, Lin SW, Askanas V. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 2005;167:517–526.
   PubMed Web of Science ®Google Scholar
• Tank SJ, Chima RS, Shah V, Malik S, Joshi S, Mazumdar RH. Renal amyloidosis following tuberculosis. Indian J Pediatr 2000;67:679–681.
   Google Scholar
• Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol 2001;13:67–73.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998;82:1501–1505.
   PubMed Web of Science ®Google Scholar
• Thomas B, Beal MF: Parkinson disease. Hum Mol Genet 2007;16:R183–R194.
   PubMed Web of Science ®Google Scholar
• Baloyannis SJ, Costa V, Baloyannis IS. Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease. J Neurol Sci 2006;248:35–41.
   Google Scholar
• Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259–272.
   PubMed Web of Science ®Google Scholar
• Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196–1203.
   PubMed Web of Science ®Google Scholar
• Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9: 92–97.
   PubMed Web of Science ®Google Scholar
• Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008;115:437–444.
   PubMed Web of Science ®Google Scholar
• Hanson JC, Lippa CF. Lewy body dementia. Int Rev Neurobiol 2009;84:215–228.
   Google Scholar
• Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007;27:494–506.
   PubMed Web of Science ®Google Scholar
• Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 1999;22:110–114.
   PubMed Web of Science ®Google Scholar
• Wheeler TC, Chin LS, Li Y, Roudabush FL, Li L. Regulation of synaptophysin degradation by mammalian homologues of seven in absentia. J Biol Chem 2002;277:10273–10282.
   PubMedGoogle Scholar
• Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356–1364.
   PubMed Web of Science ®Google Scholar
• Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605–608.
   PubMed Web of Science ®Google Scholar
• Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302–305.
   PubMed Web of Science ®Google Scholar
• Waxman EA, Giasson BI. Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta 2009;1792:616–624.
   PubMed Web of Science ®Google Scholar
• Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25: 239–252.
   PubMed Web of Science ®Google Scholar
• Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002;22:3090–3099.
   PubMed Web of Science ®Google Scholar
• Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8:600–606.
   PubMed Web of Science ®Google Scholar
• Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106–108.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di IG, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276: 2045–2047.
   PubMed Web of Science ®Google Scholar
• Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez TE, Del ST, Munoz DG, de Yebenes JG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55: 164–173.
   PubMed Web of Science ®Google Scholar
• Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci USA 2003;100;2884–2889.
   Google Scholar
• Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157:401–410.
   PubMed Web of Science ®Google Scholar
• Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 2001;15:916–926.
   PubMed Web of Science ®Google Scholar
• Li W, Lee MK. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity. J Neurochem 2005;93:1542–1550.
   Google Scholar
• Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4:1318–1320.
   PubMed Web of Science ®Google Scholar
• Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT, Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002;418:291.
   PubMed Web of Science ®Google Scholar
• Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003;300:636–640.
   PubMed Web of Science ®Google Scholar
• Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S26–S36.
   Google Scholar
• Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 2004;279:47746–47753.
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301–1306.
   PubMed Web of Science ®Google Scholar
• Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002;277: 1641–1644.
   PubMed Web of Science ®Google Scholar
• Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 2004;279:13256–13264.
   PubMed Web of Science ®Google Scholar
• Castegna A, Thongboonkerd V, Klein J, Lynn BC, Wang YL, Osaka H, Wada K, Butterfield DA. Proteomic analysis of brain proteins in the gracile axonal dystrophy (gad) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxyl-terminal hydrolase L-1, reveals oxidation of key proteins. J Neurochem 2004;88:1540–1546.
   PubMed Web of Science ®Google Scholar
• Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003;348:1365–1375.
   PubMed Web of Science ®Google Scholar
• Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;364:362.
   PubMed Web of Science ®Google Scholar
• Valentine JS, Doucette PA, Zittin PS. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem 2005;74:563–593.
   PubMed Web of Science ®Google Scholar
• Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem 1997;69:1936–1944.
   PubMed Web of Science ®Google Scholar
• Subramaniam JR, Lyons WE, Liu J, Bartnikas TB, Rothstein J, Price DL, Cleveland DW, Gitlin JD, Wong PC. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat Neurosci 2002;5:301–307.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Loeffler JP. Mitochondrial dysfunction in amyotrophic lateral sclerosis also affects skeletal muscle. Muscle Nerve 2006;34: 253–254.
   Google Scholar
• Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, Mahata J, Kilty M, Bednarz K, Bell D, Gordon PH, Hornig M, Mehrazin M, Naini A, Flint BM, Factor-Litvak P. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler 2008;9:177–183.
   PubMed Web of Science ®Google Scholar
• Brennan WA, Jr, Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985;44:1948–1950.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 2000;47:80–86.
   PubMed Web of Science ®Google Scholar
• Ashley CT, Jr, Warren ST. Trinucleotide repeat expansion and human disease. Annu Rev Genet 1995;29:703–728.
   PubMed Web of Science ®Google Scholar
• Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003;361:1642–1644.
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–596.
   PubMed Web of Science ®Google Scholar
• Perez-Severiano F, Rios C, Segovia J. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res 2000;862:234–237.
   PubMed Web of Science ®Google Scholar
• Rotig A, De LP, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997;17:215–217.
   PubMed Web of Science ®Google Scholar
• Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, Von BA, Schulz-Schaeffer W, Giese A, Westaway D, Kretzschmar H. The cellular prion protein binds copper in vivo. Nature 1997;390: 684–687.
   PubMed Web of Science ®Google Scholar
• Singh A, Kong Q, Luo X, Petersen RB, Meyerson H, Singh N. Prion protein (PrP) knock-out mice show altered iron metabolism: a functional role for PrP in iron uptake and transport. PLoS One 2009;4:e6115.
   PubMed Web of Science ®Google Scholar
• Wong BS, Liu T, Li R, Pan T, Petersen RB, Smith MA, Gambetti P, Perry G, Manson JC, Brown DR, Sy MS. Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. J Neurochem 2001;76:565–572.
   PubMed Web of Science ®Google Scholar
• Shacka JJ, Roth KA. Cathepsin deficiency as a model for neuronal ceroid lipofuscinoses. Am J Pathol 2005;167: 1473–1476.
   Google Scholar
• van Diggelen OP, Thobois S, Tilikete C, Zabot MT, Keulemans JL, van Bunderen PA, Taschner PE, Losekoot M, Voznyi YV. Adult neuronal ceroid lipofuscinosis with palmitoyl-protein thioesterase deficiency: first adult-onset patients of a childhood disease. Ann Neurol 2001;50: 269–272.
   PubMed Web of Science ®Google Scholar
• Wisniewski KE, Kida E, Walus M, Wujek P, Kaczmarski W, Golabek AA. Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders. Eur J Paediatr Neurol 2001;5(Suppl A):73–79.
   Google Scholar
• Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147–157.
   PubMed Web of Science ®Google Scholar
• Gotz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008;9: 532–544.
   PubMed Web of Science ®Google Scholar
• Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998;783:109–114.
   PubMed Web of Science ®Google Scholar
• Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci USA 2002;99:1876–1881.
   PubMed Web of Science ®Google Scholar